Cargando…

Proximal tubular renal dysfunction among HIV infected patients on Tenofovir versus Tenofovir sparing regimen in western Kenya

INTRODUCTION: Tenofovir Disoproxil Fumarate (TDF) is the most widely used Anti-Retroviral Therapy (ART) drug due to its potency, safety profile and World Health Organization (WHO) recommendation. TDF causes proximal tubular renal dysfunction (PTRD) leading to Fanconi syndrome, acute kidney injury an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Karoney, Mercy Jelagat, Koech, Mathew Kirtptonui, Njiru, Evangeline Wawira, Owino Ong’or, Willis Dixon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9477312/ https://www.ncbi.nlm.nih.gov/pubmed/36108078 http://dx.doi.org/10.1371/journal.pone.0273183

Ejemplares similares

Primary cutaneous tuberculosis in a 27-year-old medical intern from needle-stick injury: a case report
por: Karoney, Mercy Jelagat, et al.
Publicado: (2015)

Absence of HIV-Associated Nephropathy Among Antiretroviral Naive Adults With Persistent Albuminuria in Western Kenya
por: Koech, M.K., et al.
Publicado: (2016)

Reversal of tenofovir induced nephrotoxicity: case reports of two patients
por: Some, Fatuma, et al.
Publicado: (2017)

Hepatitis C virus (HCV) infection in Africa: a review
por: Karoney, Mercy Jelagat, et al.
Publicado: (2013)

Prescribing rates and characteristics of recipients of tenofovir-containing regimens before and after market entry of tenofovir alafenamide
por: Hung, Anna, et al.
Publicado: (2020)

Tenofovir is associated with increased tubular proteinuria and asymptomatic renal tubular dysfunction in Ghana
por: Chadwick, David R., et al.
Publicado: (2015)

Impact of switching to tenofovir alafenamide on weight gain as compared to maintaining a non-tenofovir alafenamide containing regimen
por: Darnell, Julia, et al.
Publicado: (2021)

A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide
por: Wassner, Chanie, et al.
Publicado: (2020)

Tenofovir Renal Proximal Tubular Toxicity Is Regulated By OAT1 and MRP4 Transporters
por: Kohler, James J., et al.
Publicado: (2011)

Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population
por: Kawuma, Aida N., et al.
Publicado: (2023)

The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: Meta-analysis
por: Wang, Huilian, et al.
Publicado: (2016)

Ganciclovir–tenofovir interaction leading to tenofovir-induced nephrotoxicity
por: Soanker, Radhika, et al.
Publicado: (2014)

Population pharmacokinetics of tenofovir and tenofovir‐diphosphate in healthy women
por: Burns, Rebecca N., et al.
Publicado: (2015)

Vaginal microbiota and mucosal pharmacokinetics of tenofovir in healthy women using tenofovir and tenofovir/levonorgestrel vaginal rings
por: Thurman, Andrea Ries, et al.
Publicado: (2019)

Proximal tubular dysfunction and kidney injury associated with tenofovir in HIV patients: a case series
por: Waheed, Sana, et al.
Publicado: (2015)

Urine Assay to Measure Tenofovir Concentrations in Patients Taking Tenofovir Alafenamide
por: Lalley-Chareczko, Linden, et al.
Publicado: (2020)

Renal safety of tenofovir containing antiretroviral regimen in a Singapore cohort
por: Chua, Arlene C, et al.
Publicado: (2012)

Proximal tubular dysfunction associated with tenofovir in an HVC-HIV co-infected patient undergoing HVC therapy
por: Fontseré, Néstor, et al.
Publicado: (2008)

Viral Blips Were Infrequent in HIV-1-Infected Virologically-Suppressed Adults Treated with Tenofovir Alafenamide or Tenofovir DF Rilpivirine-Containing Regimens
por: Wohl, David A, et al.
Publicado: (2017)

Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV
por: Plum, Pierre-Emmanuel, et al.
Publicado: (2021)

Neurological syndrome in an HIV-prevention trial participant randomized to daily tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg) in Bondo, Kenya
por: Owino, Fredrick, et al.
Publicado: (2013)

Prevalence and factors associated with chronic kidney disease among medical inpatients at the Kenyatta National Hospital, Kenya, 2018: a cross-sectional study
por: Mwenda, Valerian, et al.
Publicado: (2019)

Review of tenofovir-emtricitabine
por: Masho, Saba Woldemichael, et al.
Publicado: (2007)

Chemoenzymatic Synthesis of Tenofovir
por: Zdun, Beata, et al.
Publicado: (2023)

Severe abacavir hypersensitivity reaction in a patient with human immunodeficiency virus infection: a case report
por: Koech, Mathew K., et al.
Publicado: (2022)

Efficacy of topical tenofovir against transmission of a tenofovir-resistant SHIV in macaques
por: Dobard, Charles W, et al.
Publicado: (2015)

Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide
por: Funderburg, Nicholas T., et al.
Publicado: (2016)

Real-world impact of switching from tenofovir disoproxil fumarate to tenofovir alafenamide
por: Michienzi, Sarah M, et al.
Publicado: (2021)

Tenofovir disoproxil fumarate-associated renal tubular dysfunction: noninvasive assessment of mitochondrial injury
por: Samuels, Ryan, et al.
Publicado: (2017)

Recovery of Tenofovir-induced Nephrotoxicity following Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Human Immunodeficiency Virus-Positive Patients
por: Seo, Jun-Won, et al.
Publicado: (2020)

Lower Urine Tenofovir Concentrations Among Individuals Taking Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate: Implications for Point-of-Care Testing
por: Johnson, Kelly A, et al.
Publicado: (2021)

Genital microbiota of women using a 90 day tenofovir or tenofovir and levonorgestrel intravaginal ring in a placebo controlled randomized safety trial in Kenya
por: Dabee, Smritee, et al.
Publicado: (2022)

Randomized controlled phase IIa clinical trial of safety, pharmacokinetics and pharmacodynamics of tenofovir and tenofovir plus levonorgestrel releasing intravaginal rings used by women in Kenya
por: Mugo, Nelly R., et al.
Publicado: (2023)

1014. Factors Associated with Switching from Tenofovir Diproxil Phosphate to a Tenofovir Alafenamide Based Regimen in a Cohort with Unrestricted Access to Care and Medications
por: Ganesan, Anuradha, et al.
Publicado: (2020)

Delayed onset renal failure in a patient on tenofovir based antiretroviral regimen
por: Krishna, M. Murali, et al.
Publicado: (2014)

Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?
por: Hill, Andrew, et al.
Publicado: (2018)

Tenofovir Alafenamide in Multimorbid HIV-Infected Patients With Prior Tenofovir-Associated Renal Toxicity
por: Walti, Laura N, et al.
Publicado: (2018)

Atherosclerotic Cardiovascular Disease Risk Profile of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate
por: Huhn, Gregory D, et al.
Publicado: (2019)

Comparative pharmacokinetics between tenofovir disoproxil phosphate and tenofovir disoproxil fumarate in healthy subjects
por: Lee, Sangmi, et al.
Publicado: (2021)

Adherence Predictors in Pregnant Women Living with HIV on Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate
por: Eke, Ahizechukwu C
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0i93dgbjku7ag9qnegbr26ei85